Skip to main content

Table 5 Sensitivity analysis using inverse probably treatment weighting

From: Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis

 

Before propensity score matching

After propensity score matching

Hazard ratio (95% CI)

p value

 

No metformin (n = 2222)

Metformin (n = 1377)

No metformin (n = 2222)

Metformin (n = 1377)

Death

25.1 (23.3, 27.1)

10.5 (8.7, 12.5)

22.5 (20.7, 24.6)

11.6 (9.2, 14.7)

0.46 (0.36, 0.58)

 < 0.001

Hospitalization

76.1 (72.0, 80.6)

55.12 (50.4, 60.3)

70.8 (65.7, 76.3)

63.4 (55.7, 72.3)

0.81 (0.72, 0.92)

0.001